The Zhitong Finance App learned that UBS gave Novo Nordisk (NVO.US) a 12-month target price of 750 Danish kroner based on projected earnings per share (EPS) for FY2025, combined industry valuations, growth potential compared to peers, and the PharmaValues NPV valuation model, and reaffirmed the “buy” rating. UBS believes Novo Nordisk's leading position in the treatment of diabetes and obesity, as well as its strong R&D pipeline, makes it a long-term investment.

Zhitongcaijing · 05/08 08:25
The Zhitong Finance App learned that UBS gave Novo Nordisk (NVO.US) a 12-month target price of 750 Danish kroner based on projected earnings per share (EPS) for FY2025, combined industry valuations, growth potential compared to peers, and the PharmaValues NPV valuation model, and reaffirmed the “buy” rating. UBS believes Novo Nordisk's leading position in the treatment of diabetes and obesity, as well as its strong R&D pipeline, makes it a long-term investment.